FDA officially announced: Pfizer Pharmaceuticals developed a specific drug for new coronary pneumonia on the market at the end of December
On December 26, the U.S. Food and Drug Administration officially announced that Pfizer Pharmaceuticals, a specific drug for new coronary pneumonia, will be marketed and sold in all parts of the United States in the last week of this month (December). Supply high-risk groups (over 65 years old). This is the last battle against the new crown pneumonia in the United States and the world. Pfizer Pharmaceuticals announced a month ago that once the FDA passes, it will publish patents, allowing impermanent manufacturing in countries around the world. We finally look forward to the day when we finally defeat the new crown virus.
The name of the drug is Paxlovid, which is a capsule that you can buy in the pharmacy and take it yourself when you go home. Just like ordinary cold medicine. The data released by the FDA for this drug are as follows: Safety: After 20,000 people took the drug in a trial, there was no death, and only 19.8% of the stations had a mild reaction. Course of treatment: Take three capsules twice a day for five days. The effect of severe illness, 1. Three days after the onset of the disease, I started to take this medicine, and 89% recovered after 5 days of taking the medicine. 2. After five days of onset, I started taking this medicine, and 88% recovered after 5 days. For the rest, all healed after two courses of treatment. The biggest advantage has the same effect on all mutated new coronary pneumonia viruses.
This time there is finally hope that the new crown epidemic can be brought under control, and I hope that the world will return to the state of free exchanges in 2019 as soon as possible.